We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Caredx Inc (CDNA) USD0.001

Sell:$43.82 Buy:$43.91 Change: $0.74 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.74 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.74 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, which is a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap Heart, which is a gene expression solution for heart transplant patients, and AlloSure Heart, a dd-cf-DNA solution for heart transplant patients. Its suite of AlloSeq products include: AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. It also provides transplant patient tracking software, Ottr software, as well as of transplant quality tracking and waitlist management solutions.

Contact details

1 Tower Place, 9Th Floor
United States
+1 (415) 2872300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.20 billion
Shares in issue:
52.80 million
United States
US dollar

Key personnel

  • Reginald Seeto
    President, Chief Executive Officer, Director
  • Ankur Dhingra
    Chief Financial Officer
  • Sasha King
    Chief Marketing Officer
  • Alexander Johnson
    Chief Business Officer and Head of Testing Services

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.